[
  {
    "ts": null,
    "headline": "The Patients Forced to Switch From Zepbound to Wegovy",
    "summary": "Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.",
    "url": "https://finnhub.io/api/news?id=8af92a444ea5ee5d775a5d71e4b8825904c18ba2fc04a5c7e72e53b111cacf48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753628220,
      "headline": "The Patients Forced to Switch From Zepbound to Wegovy",
      "id": 136101658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.",
      "url": "https://finnhub.io/api/news?id=8af92a444ea5ee5d775a5d71e4b8825904c18ba2fc04a5c7e72e53b111cacf48"
    }
  },
  {
    "ts": null,
    "headline": "Leerink Partners and Jefferies Issue Bullish Ratings on Eli Lilly and Company (LLY)",
    "summary": "Eli Lilly and Company (NYSE:LLY) is among the 12 Best Ethical Companies to Invest in 2025. Eli Lilly and Company (NYSE:LLY) is experiencing a strong analyst sentiment amid its expanding role in cutting-edge treatments. On July 18, Leerink Partners maintained its ‘Buy’ rating on the company, citing growth potential through the GLP-1 receptor agonist (GLP-1RA) […]",
    "url": "https://finnhub.io/api/news?id=bb2cc2610949310ed9d7407c056349e99460d467d9bbb19434d3a9b6c480537a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753625709,
      "headline": "Leerink Partners and Jefferies Issue Bullish Ratings on Eli Lilly and Company (LLY)",
      "id": 136101659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is among the 12 Best Ethical Companies to Invest in 2025. Eli Lilly and Company (NYSE:LLY) is experiencing a strong analyst sentiment amid its expanding role in cutting-edge treatments. On July 18, Leerink Partners maintained its ‘Buy’ rating on the company, citing growth potential through the GLP-1 receptor agonist (GLP-1RA) […]",
      "url": "https://finnhub.io/api/news?id=bb2cc2610949310ed9d7407c056349e99460d467d9bbb19434d3a9b6c480537a"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Magellan Fund Q2 2025 Commentary",
    "summary": "For the first quarter of 2025, the fund's Retail Class shares returned -5.87%, trailing the -4.27% advance of the benchmark S&P 500 (SP500), (SPX) index.U.S.",
    "url": "https://finnhub.io/api/news?id=00fb5ea88d0fc041ebc8afd11a8934e0d3a35645a4d92eeb493319ea0e8794ee",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753580400,
      "headline": "Fidelity Magellan Fund Q2 2025 Commentary",
      "id": 136099320,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1752097598/image_1752097598.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For the first quarter of 2025, the fund's Retail Class shares returned -5.87%, trailing the -4.27% advance of the benchmark S&P 500 (SP500), (SPX) index.U.S.",
      "url": "https://finnhub.io/api/news?id=00fb5ea88d0fc041ebc8afd11a8934e0d3a35645a4d92eeb493319ea0e8794ee"
    }
  }
]